Issue 5, 2016

Surface defection reduces cytotoxicity of Zn(2-methylimidazole)2 (ZIF-8) without compromising its drug delivery capacity

Abstract

Zn(2-methylimidazole)2 (ZIF-8), as one of the most important metal–organic framework (MOF) molecules, is a promising candidate for drug delivery due to its low-density structure, high surface area, and tunable frameworks. However, ZIF-8 exhibits a high cytotoxicity associated with its external hydrophobic surface, which significantly restricts its application in drug delivery and other biomedical applications. Commonly used chemical functionalization methods would convert the hydrophobic surface of ZIF-8 to hydrophilic, but the generated functional groups on its internal surface may reduce its pore sizes or even block its pores. Herein, a surface defection strategy was applied on the external surface of ZIF-8 to enhance its hydrophilicity without reducing or blocking the internal pores. In this approach, mechanical ball-milling was used to incur defects on the external surface of ZIF-8, leading to unsaturated Zn-sites and N-sites which subsequently bound H2O molecules in an aqueous environment. Furthermore, hydroxyurea delivery and cell cytotoxicity of ZIF-8 with and without the external surface treatment were evaluated. It was found that 5 min ball milling changed the hydrophobic–hydrophilic balance of ZIF-8, resulting in significantly higher cell viability without compromising its hydroxyurea loading and release capacity. Such a simple mechanical ball-milling followed by water-treatment provides a general technique for surface-modification of other MOF molecules, which will undoubtedly magnify their biomedical applications.

Graphical abstract: Surface defection reduces cytotoxicity of Zn(2-methylimidazole)2 (ZIF-8) without compromising its drug delivery capacity

Supplementary files

Article information

Article type
Paper
Submitted
17 نومبر 2015
Accepted
16 دسمبر 2015
First published
18 دسمبر 2015

RSC Adv., 2016,6, 4128-4135

Surface defection reduces cytotoxicity of Zn(2-methylimidazole)2 (ZIF-8) without compromising its drug delivery capacity

E. Shearier, P. Cheng, Z. Zhu, J. Bao, Y. H. Hu and F. Zhao, RSC Adv., 2016, 6, 4128 DOI: 10.1039/C5RA24336J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements